Crossmark

Allicin inhibits kidney stone formation by suppressing the TNF/NF-κB pathway: Experimental validation through network pharmacology, in vitro, and in vivo studies

Crossref DOI link: https://doi.org/10.1007/s11033-026-12089-y

Published Online: 2026-06-10

Published Print: 2026-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Peng, Zechun

Xu, Mingbin

Yang, Jie

He, Shuming
Funding

Funding for this research was provided by:

the Joint Program on Health Science & Technology Innovation of Hainan Province (WSJK2025QN078)
License Information

Text and Data Mining valid from 2026-06-10

Version of Record valid from 2026-06-10
More Information

Article History

Received: 22 April 2026

Accepted: 29 May 2026

First Online: 10 June 2026

Declarations

:

: The experimental protocol was approved by the Ethics Committee of Hainan Medical University (Approval No. HYLL-2024-614). All animal experiments were performed in accordance with the relevant guidelines and regulations for the care and use of laboratory animals.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below